News und Analysen
DGAP-News: NanoRepro AG: Klinische Studien zur Sensitivität der Schnelltests bei der Omikron-Variante
DGAP-News: NanoRepro AG: Klinische Studien zur Sensitivität der Schnelltests bei der Omikron-Variante
Edison Investment Research Limited: Agronomics (ANIC) Initiation - At the forefront of a new agrarian revolution
Edison Investment Research Limited: Agronomics (ANIC) Initiation - At the forefront of a new agrarian revolution
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
DGAP-Adhoc: NanoRepro AG: Änderung Prognose 2021 und Ausblick 2022 mit Dividende
DGAP-Adhoc: NanoRepro AG: Änderung Prognose 2021 und Ausblick 2022 mit Dividende
DGAP-News: NanoRepro AG: Neues Aufsichtsratsmitglied wird gerichtlich bestellt
DGAP-News: NanoRepro AG: Neues Aufsichtsratsmitglied wird gerichtlich bestellt
EQS-Adhoc: Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
EQS-Adhoc: Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
EQS-Adhoc: Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
EQS-Adhoc: Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
DGAP-News: NanoRepro AG: Zuverlässiger Nachweis auch bei Omikron-Variante
DGAP-News: NanoRepro AG: Zuverlässiger Nachweis auch bei Omikron-Variante
EQS-Adhoc: Relief Therapeutics Announces Executive Changes
EQS-Adhoc: Relief Therapeutics Announces Executive Changes
EQS-Adhoc: Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
EQS-Adhoc: Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
DGAP-Adhoc: CytoTools AG: Aufsichtsrat und Vorstand beschließen langfristige Finanzierungsinstrumente der CytoTools AG
DGAP-Adhoc: CytoTools AG: Aufsichtsrat und Vorstand beschließen langfristige Finanzierungsinstrumente der CytoTools AG
EQS-Adhoc: Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
EQS-Adhoc: Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil